Randomised trial shows intravenous iron significantly improves maternal haemoglobin before delivery in non-anaemic iron ...
Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of ...
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with ...
Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity Viatris Chief R&D Officer Philippe Martin said, ...
IntravenoIron Drugs Market, By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Others), and By ...
Explore the critical role of iron in nutrition and its impact on health, growth, and development in populations.
Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including gastrointestinal adverse effects and poor absorption, leading many patients to ...
On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...
Intravenous (IV) iron therapy is more effective than oral drugs for women with anemia and heavy periods, providing better ...
Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH, Aug. 11, 2025 /PRNewswire/ -- Viatris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback